Breast Cancer Highlights from 2023: ASK THE EXPERT

Breast Cancer Highlights from 2023: ASK THE EXPERT

Icon Objectives

Learning Objectives

  1. Articulate appropriate applications and interpretations of significant 2023 research data in breast cancer
  2. Understand how clinicians can integrate evidence-based treatment choices into practice
  3. Review significant data presented this year from key oncology conferences to improve patient management and outcomes
Icon Panelists

Speakers

Dr. Jan-Willem Henning
Dr. Paolo Tarantino

This program has been made possible through unrestricted support from AstraZeneca and Daiichi Sankyo

Studies/trials discussed:

  • NATALEE phase 3 trial
  • PALLAS trial
  • Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
  • PENELOPE-B trial
  • Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
  • KATHERINE study
  • DESTINY Breast-06 study
  • DESTINY Breast-06 phase 3 trial
  • CAPitello-291 trial
  • INAVO120 trial
  • EPIK-B5 study
Tagged